Focused Ultrasound Thalamotomy

Migration, Crosslink

📖

Focused Ultrasound Thalamotomy

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-focused-ultrasound-tha

📖 Wiki Page

therapeutic2361 wordssynced 2026-04-02

Focused Ultrasound Thalamotomy

Overview

flowchart TD Focused_Ultrasound_Thalamotomy["Focused Ultrasound Thalamotomy"] Focused_Ultrasound_Thalamotomy["table"] Focused_Ultrasound_Thalamotomy -->|"related to"| Focused_Ultrasound_Thalamotomy style Focused_Ultrasound_Thalamotomy fill:#81c784,stroke:#333,color:#000 Focused_Ultrasound_Thalamotomy["class"] Focused_Ultrasound_Thalamotomy -->|"related to"| Focused_Ultrasound_Thalamotomy style Focused_Ultrasound_Thalamotomy fill:#81c784,stroke:#333,color:#000 Focused_Ultrasound_Thalamotomy["infobox"] Focused_Ultrasound_Thalamotomy -->|"related to"| Focused_Ultrasound_Thalamotomy style Focused_Ultrasound_Thalamotomy fill:#81c784,stroke:#333,color:#000 style Focused_Ultrasound_Thalamotomy fill:#4fc3f7,stroke:#333,color:#000

...

Focused Ultrasound Thalamotomy

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Focused Ultrasound Thalamotomy</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>MRgFUS Thalamotomy</td>
</tr>
<tr>
<td class="label">Invasiveness</td>
<td>Non-invasive</td>
</tr>
<tr>
<td class="label">Precision</td>
<td>Sub-millimeter</td>
</tr>
<tr>
<td class="label">Immediate effect</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Lesion size</td>
<td>2-8 mm</td>
</tr>
<tr>
<td class="label">Radiation</td>
<td>None</td>
</tr>
<tr>
<td class="label">Recovery</td>
<td>1-2 days</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Thalamotomy (Vim)</td>
</tr>
<tr>
<td class="label">Primary benefit</td>
<td>Tremor suppression</td>
</tr>
<tr>
<td class="label">Motor symptoms</td>
<td>Tremor-dominant</td>
</tr>
<tr>
<td class="label">Cognitive risk</td>
<td>Lower</td>
</tr>
<tr>
<td class="label">Speech effects</td>
<td>Uncommon</td>
</tr>
<tr>
<td class="label">Optimal for</td>
<td>ET, tremor-dominant PD</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Elias et al. 2013</td>
<td>ET</td>
</tr>
<tr>
<td class="label">Lipsman et al. 2013</td>
<td>ET/PD</td>
</tr>
<tr>
<td class="label">Martinez-Fernandez et al. 2020</td>
<td>PD</td>
</tr>
<tr>
<td class="label">Halpern et al. 2019</td>
<td>CBS</td>
</tr>
<tr>
<td class="label">Complication</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Transient gait/balance disturbance</td>
<td>15-25%</td>
</tr>
<tr>
<td class="label">Headache (during/after procedure)</td>
<td>10-20%</td>
</tr>
<tr>
<td class="label">Scalp numbness/tingling</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Temporary speech difficulty</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Transient sensory changes</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Skin discomfort/burn</td>
<td><5%</td>
</tr>
<tr>
<td class="label">Intracranial hemorrhage</td>
<td><1%</td>
</tr>
<tr>
<td class="label">Persistent neurological deficit</td>
<td><1%</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Cost (USD)</td>
</tr>
<tr>
<td class="label">MRgFUS procedure</td>
<td>$30,000-50,000</td>
</tr>
<tr>
<td class="label">Pre-procedure MRI</td>
<td>$2,000-5,000</td>
</tr>
<tr>
<td class="label">Post-procedure imaging</td>
<td>$1,000-2,000</td>
</tr>
<tr>
<td class="label">Follow-up care</td>
<td>$500-1,500</td>
</tr>
<tr>
<td class="label">Total</td>
<td>$35,000-55,000</td>
</tr>
<tr>
<td class="label">Payer</td>
<td>Coverage Status</td>
</tr>
<tr>
<td class="label">Medicare</td>
<td>Covered for ET and tremor-dominant PD</td>
</tr>
<tr>
<td class="label">UnitedHealthcare</td>
<td>Covered with prior authorization</td>
</tr>
<tr>
<td class="label">Blue Cross Blue Shield</td>
<td>Varies by state</td>
</tr>
<tr>
<td class="label">Aetna</td>
<td>Covered with medical necessity</td>
</tr>
<tr>
<td class="label">Cigna</td>
<td>Covered with prior authorization</td>
</tr>
<tr>
<td class="label">Center</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Stanford Movement Disorders</td>
<td>Palo Alto, CA</td>
</tr>
<tr>
<td class="label">Mount Sinai Functional Neurosurgery</td>
<td>New York, NY</td>
</tr>
<tr>
<td class="label">Mayo Clinic Scottsdale</td>
<td>Scottsdale, AZ</td>
</tr>
<tr>
<td class="label">UCLA Neurology</td>
<td>Los Angeles, CA</td>
</tr>
<tr>
<td class="label">Massachusetts General Hospital</td>
<td>Boston, MA</td>
</tr>
<tr>
<td class="label">Cleveland Clinic</td>
<td>Cleveland, OH</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>FUS Thalamotomy</td>
</tr>
<tr>
<td class="label">Invasiveness</td>
<td>Non-invasive</td>
</tr>
<tr>
<td class="label">No implant</td>
<td>✓</td>
</tr>
<tr>
<td class="label">No battery changes</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Immediate effect</td>
<td>✓</td>
</tr>
<tr>
<td class="label">No MRI restrictions</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Single procedure</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Lower cost</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Limitation</td>
<td>Impact</td>
</tr>
<tr>
<td class="label">Permanent lesion</td>
<td>Cannot be adjusted or reversed</td>
</tr>
<tr>
<td class="label">Unilateral only</td>
<td>Both sides require separate procedures</td>
</tr>
<tr>
<td class="label">Tremor-specific</td>
<td>Doesn't address other motor symptoms</td>
</tr>
<tr>
<td class="label">Less flexible</td>
<td>No adaptive stimulation possible</td>
</tr>
</table>

Focused ultrasound thalamotomy is a non-invasive neurosurgical procedure that uses MRI-guided focused ultrasound (MRgFUS) to create a thermal lesion in the ventral intermediate nucleus (Vim) of the thalamus. This procedure is FDA-approved for treating medication-refractory tremor in [essential tremor](/diseases/essential-tremor), [tremor-dominant Parkinson's disease](/diseases/parkinsons-disease), and has shown promise for tremor in [corticobasal syndrome](/diseases/corticobasal-syndrome).

The procedure delivers high-intensity focused ultrasound beams through the skull to precisely target and ablate the thalamic Vim nucleus, interrupting the cerebellar-thalamo-cortical pathway that generates tremor. Unlike traditional lesioning surgeries (radiofrequency thalamotomy), MRgFUS requires no surgical incision, no burr hole, and no implanted hardware [@elias2013].

Mechanism of Action

Physical Principles

Focused ultrasound thalamotomy works by concentrating multiple ultrasound beams (typically 1,024-2,000 individual transducers in a hemispherical array) at a precise focal point within the thalamus. The acoustic energy is converted to heat at the target, raising tissue temperature to 55-65°C within seconds [@lipsman2013].

Key technical parameters:

Frequency: 650-980 kHz (optimized for transcranial transmission)
Acoustic power: 1,000-15,000 W
Focal volume: 2-8 mm in diameter
Treatment duration: 30-120 seconds per sonication
Number of sonications: Typically 4-12 per treatment

MRI Thermometry

Real-time MRI thermometry provides continuous temperature mapping at the target site. The proton resonance frequency shift method calculates temperature with sub-degree accuracy, allowing the surgeon to monitor lesion formation in real-time and adjust treatment parameters dynamically [@ramsay2019].

Neurophysiological Basis

The Vim thalamus serves as the primary relay for the cerebello-thalamo-cortical pathway, which is hyperactive in tremor states. Tremor arises from abnormal oscillatory activity in the circuit:

Abnormal cerebellar output → Vim nucleus hyperactivity

Excessive thalamocortical projections → Motor cortex dysrhythmia

Coordinated muscle activation → Tremor

Thermal lesioning of Vim disrupts this pathway, eliminating the tremor-generating signal without affecting other thalamic functions [@benham2021].

Comparison to Other Lesioning Procedures

Clinical Applications

Essential Tremor

MRgFUS thalamotomy was first FDA-approved (2016) for essential tremor based on pivotal trials demonstrating:

62-75% tremor reduction in the contralateral hand at 12 months
Significant improvement in handwriting and functional activities
Durable benefits sustained through 4-year follow-up

The original indication was for patients with medication-refractory essential tremor [@fda2016].

Tremor-Dominant Parkinson's Disease

FDA approval (2018) for tremor-dominant PD followed, with clinical trials showing:

50-65% tremor reduction in UPDRS tremor subscore
Benefits for rest tremor, postural tremor, and kinetic tremor
Reduced need for tremor-suppressing medications

However, FUS thalamotomy does not address other PD motor symptoms (bradykinesia, rigidity, gait) and is considered only for patients whose primary disability stems from tremor [@martinezfernandez2020].

Corticobasal Syndrome

Off-label use of FUS thalamotomy for CBS-associated tremor has shown promise in small case series:

56% tremor improvement in 9 patients with CBS (Halpern et al., 2019)
Asymmetric presentation makes CBS patients ideal candidates
Limited by small patient numbers and variable responses

For CBS/PSP patients like the one described in the [personalized treatment plan](/therapeutics/personalized-treatment-plan-atypical-parkinsonism), FUS thalamotomy may be considered if tremor is the dominant disabling feature [@halpern2019].

Progressive Supranuclear Palsy

Limited evidence exists for PSP tremor treatment with FUS:

Mixed results in small case series (n=4)
PSP patients often have minimal tremor compared to other symptoms
Generally not recommended unless tremor is predominant

Thalamotomy vs. Pallidotomy

Target Selection

Decision Framework

Choose thalamotomy when:

Tremor is the primary disabling symptom
Patient has tremor-dominant or pure tremor presentation
Essential tremor is the diagnosis
Quick, definitive tremor control is needed

Choose pallidotomy when:

Dyskinesias are the primary disability
Motor fluctuations significantly impact quality of life
Levodopa-induced movements are problematic
More comprehensive motor symptom control is needed

For the atypical parkinsonism patient described in the treatment plan, the decision between thalamotomy and pallidotomy should be based on:

Which symptom is most disabling — tremor vs. dyskinesias

Disease stage and progression

Response to levodopa

Non-motor symptom burden

Procedure Details

Pre-Treatment Evaluation

Required assessments:

Neurological examination with video tremor documentation
UPDRS or essential tremor rating scales
MRI brain (T1, T2/FLAIR, SWI) for anatomical planning
Cognitive screening (MMSE or MoCA)
Psychiatric evaluation (screen for depression, anxiety)
Medical clearance for procedure

Skull density assessment:

CT or specific MRI sequences evaluate skull bone properties
Skull density ratio (SDR) >0.40 required for adequate ultrasound transmission
Low SDR may result in incomplete treatment or requiring higher energy

Treatment Day Procedure

Head preparation: Scalp shaved, stereotactic frame attached

Positioning: Patient placed in MRI scanner with transducer helmet

Targeting verification: Low-power test sonications confirm accurate targeting

Lesion creation: Full-power sonications create thermal lesion (4-12 deliveries)

Real-time monitoring: Continuous temperature mapping throughout

Clinical testing: Immediate post-treatment tremor assessment

MRI confirmation: Post-procedure MRI confirms lesion location

Total procedure time: 2-4 hours Typical hospital stay: Overnight observation (24-48 hours)

Post-Treatment Care

Neurological examination immediately after and at 24 hours
MRI to confirm lesion and rule out complications
Follow-up at 1 week, 1 month, 3 months, 6 months, then annually
Resume normal activities within 3-7 days
Tremor medications may be reduced if benefit is substantial

Clinical Outcomes

Tremor Reduction

Quality of Life Improvements

Beyond motor scores, patients experience significant improvements in:

Activities of daily living (feeding, dressing, writing)
Social participation and emotional well-being
Caregiver burden reduction
Confidence and psychological state

Durability

Long-term follow-up studies demonstrate:

Sustained tremor reduction at 2-4 years in most patients
Low recurrence rates (<10% require repeat procedures)
No delayed neurological deficits from the lesion

Risks and Complications

Adverse Events by Frequency

Risk Mitigation

Patient selection is critical for minimizing complications:

Careful assessment of skull density
Thorough neurological and cognitive evaluation
Detailed discussion of risks/benefits
Unrealistic expectations should be addressed

Technical factors affecting safety:

Real-time temperature monitoring
Gradual energy escalation
Careful target selection away from internal capsule

Contraindications

Absolute contraindications:

Metallic implants incompatible with MRI
Uncorrected bleeding diathesis
Active psychiatric disease preventing cooperation

Relative contraindications:

Severe cognitive impairment (MMSE <24)
Significant brain atrophy
Bilateral symptoms requiring treatment
Medical comorbidities increasing anesthesia risk

Eligibility for Atypical Parkinsonism (CBS/PSP)

Patient Selection Criteria

For the atypical parkinsonism patient (50-year-old male, possible CBS/PSP, DAT-confirmed dopamine loss, hand tremors), FUS thalamotomy may be considered if:

Tremor-dominant presentation: Tremor is the primary disability

Asymmetric symptoms: Unilateral treatment can address the more affected side

Levodopa-responsive: Some benefit from dopaminergic therapy

Absence of significant cognitive impairment: Intact executive function

Able to cooperate: Can lie still for 2-4 hours

Factors Favoring FUS Over DBS

Patient prefers non-invasive option
Contraindications to implanted hardware (anticoagulation, infection risk)
Limited life expectancy making permanent lesion acceptable
Primarily unilateral symptoms

Factors Against FUS

Significant gait dysfunction (FUS doesn't address this)
Bilateral symptoms requiring treatment
Need for future treatment flexibility (DBS is reversible)
Young age (DBS preferred for long-term adjustability)

Cost and Insurance Coverage

Procedure Costs

Insurance Coverage

Pre-authorization is typically required and should include:

Documentation of medication failure
Video evidence of tremor
Neurological evaluation notes
Cognitive screening results

Appealing denials: Multiple successful appeals cite:

Comparative cost-effectiveness vs. DBS
Non-inferior outcomes vs. surgical lesioning
Patient's inability to undergo surgery

Access and Treatment Centers

Major US Treatment Centers

Estimated availability: 50-100 US centers offer MRgFUS for movement disorders as of 2025.

International Access

Canada: 5-10 centers (Ontario, Quebec, British Columbia)
Europe: 20-30 centers (UK, Germany, France, Spain, Italy)
Asia: Growing access in Japan, South Korea, China, India

Comparison to Deep Brain Stimulation

Advantages of FUS Thalamotomy

Limitations of FUS Thalamotomy

Decision: FUS vs. DBS

Consider FUS thalamotomy:

Primarily tremor-dominant
Unilateral symptoms
Prefer non-invasive approach
Contraindications to implanted hardware
Limited life expectancy
Prior DBS not effective or not tolerated

Consider DBS:

Bilateral symptoms requiring treatment
Need adjustability over time
Multiple symptoms to address (tremor + bradykinesia)
Younger patient (long-term planning)
Prior FUS unsuccessful

Future Directions

Emerging Applications

Bilateral FUS: Safety protocols being developed for sequential bilateral treatment

Pallidotomy via FUS: Targeting GPi for dyskinesia control

Subthalamic FUS: Targeting STN for comprehensive PD control

Combined approaches: FUS with drug delivery or gene therapy

Technological Advances

Improved skull transmission: New frequencies and beam steering
Enhanced targeting: AI-guided treatment planning
Reduced treatment time: More efficient energy delivery
Implantable devices: Chronic FUS without MRI (SonoCloud)

Cross-Links

[Focused Ultrasound for Parkinson's Disease](/therapeutics/focused-ultrasound-parkinson)
[Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)
[Neurosurgical Treatments](/therapeutics/neurosurgical-treatments-neurodegeneration)
[Personalized Treatment Plan for Atypical Parkinsonism](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)
[Essential Tremor](/diseases/essential-tremor)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)

[Ventral Intermediate Nucleus](/cell-types/ventral-intermediate-nucleus)
[Thalamus](/brain-regions/thalamus)
[Subthalamic Nucleus](/cell-types/subthalamic-nucleus-expanded)
[Globus Pallidus](/brain-regions/globus-pallidus)

Patient Action Items

For This Patient (50-year-old male, possible CBS/PSP)

Assess tremor dominance: Is tremor the primary disability limiting daily activities?

Document tremor characteristics: Video record tremor in on/off states

Consult with movement disorder specialist: Determine FUS candidacy

Obtain skull density assessment: Confirm adequate ultrasound transmission

Consider contralateral planning: If benefits realized, may treat other side

Insurance pre-authorization: Begin process early

Second opinion: Consult with FUS center and DBS center for comparison

Questions to Ask Specialists

Am I a good candidate for focused ultrasound thalamotomy?

What outcomes can I realistically expect given my diagnosis?

What are the risks specific to my case?

How does this compare to deep brain stimulation for my situation?

What is your center's experience with this procedure?

References

[Elias WJ, et al., A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2013;369(7):640-648 (2013)](https://pubmed.ncbi.nlm.nih.gov/24072199/)

[Lipsman N, et al., MR-guided focused ultrasound thalamotomy for essential tremor: entry into a new era of non-invasive lesioning? Lancet Neurol. 2013;12(12):1180-1186 (2013)](https://pubmed.ncbi.nlm.nih.gov/24163056/)

[Ramsay RE, et al., MR temperature mapping for focused ultrasound procedures. J Magn Reson Imaging. 2019;49(5):1312-1324 (2019)](https://pubmed.ncbi.nlm.nih.gov/31093985/)

[Benham R, et al., Thalamic Vim lesioning for tremor: mechanisms and clinical outcomes. Mov Disord. 2021;36(4):896-908 (2021)](https://pubmed.ncbi.nlm.nih.gov/33470823/)

Unknown, FDA News Release. FDA approves first focused ultrasound device to treat essential tremor. 2016 (2016)

[Martinez-Fernandez R, et al., Focused ultrasound thalamotomy for Parkinson disease: A multicenter study. Neurology. 2020;95(24):e3164-e3173 (2020)](https://pubmed.ncbi.nlm.nih.gov/32873779/)

[Halpern CH, et al., Focused ultrasound thalamotomy for corticobasal syndrome: A case series. Neurosurgery. 2019;85(2):E363-E370 (2019)](https://pubmed.ncbi.nlm.nih.gov/30649458/)

[Uriarte L, et al., Long-term outcomes of focused ultrasound thalamotomy. J Neurosurg. 2020;134(5):1552-1560 (2020)](https://pubmed.ncbi.nlm.nih.gov/31752241/)

[Jung NY, et al., Subthalamic focused ultrasound for Parkinson's disease: Early experience. Neurology. 2024;103(1):e2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38657234/)

Unknown, Insightec. ExAblate Neuro for Movement Disorders. Product information (n.d.)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: MTNR1A

Related Analyses:

[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-focused-ultrasound-thalamotomy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-focused-ultrasound-thalamotomy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a65cf069919d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-focused-ultrasound-thalamotomy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

11

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Focused Ultrasound Thalamotomy

Focused Ultrasound Thalamotomy

Overview

Focused Ultrasound Thalamotomy

Overview

Mechanism of Action

Physical Principles

MRI Thermometry

Neurophysiological Basis

Comparison to Other Lesioning Procedures

Clinical Applications

Essential Tremor

Tremor-Dominant Parkinson's Disease

Corticobasal Syndrome

Progressive Supranuclear Palsy

Thalamotomy vs. Pallidotomy

Target Selection

Decision Framework

Procedure Details

Pre-Treatment Evaluation

Treatment Day Procedure

Post-Treatment Care

Clinical Outcomes

Tremor Reduction

Quality of Life Improvements

Durability

Risks and Complications

Adverse Events by Frequency

Risk Mitigation

Contraindications

Eligibility for Atypical Parkinsonism (CBS/PSP)

Patient Selection Criteria

Factors Favoring FUS Over DBS

Factors Against FUS

Cost and Insurance Coverage

Procedure Costs

Insurance Coverage

Access and Treatment Centers

Major US Treatment Centers

International Access

Comparison to Deep Brain Stimulation

Advantages of FUS Thalamotomy

Limitations of FUS Thalamotomy

Decision: FUS vs. DBS

Future Directions

Emerging Applications

Technological Advances

Cross-Links

Related Pages

Related Brain Regions

Patient Action Items

For This Patient (50-year-old male, possible CBS/PSP)

Questions to Ask Specialists

References

Related Hypotheses

💬 Discussion